Skip to main content

Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.

Serological survey provides insight grouped age gap measles-specific immunity and the expected prevalence of a certain age. The purpose Ovine Clia Kits of this study was to describe the sero-epidemiology of measles in Vojvodina before the outbreak in 2017/18 and to discuss preventive measures for the future potential epidemics.

A seroprevalence study was conducted from April 2015 to June 2017 by the 3199 serum samples leftovers , The study was conducted prior to the last measles outbreak in Vojvodina which occurred between 12 November 2017 and June 30, 2018. Measles-specific IgG antibodies were determined by using indirect chemiluminescent immunoassay (CLIA) registered participants .Median age was 20 years (IQR 11- 37). Overall, 86.9% of serum samples were seropositive. The highest proportion of measles seronegativity observed in children aged 12-23 months and in adults aged 20-39 years (56.1% and 18.5%, respectively). 

The prevalence of measles seronegativity above the WHO target level of susceptibility was observed in the following age groups: 2, 7, 13, 15, and among all adults aged between 20 and 49 years old. Of the total cases of measles outbreaks (177), there were 91 (51.4%) participants aged 20-39 years. A significant positive correlation was observed between measles seronegativity and the number of reported measles cases aged ≥ 12 months (r = 0.4675, p = 0.0213) .I

n order to prevent new outbreaks and achieve the elimination of measles in Vojvodina, the second measles vaccination coverage -gondong-rubella (MMR1 and MMR2) vaccine needs upgraded and maintained. education campaign to increase acceptance and timely vaccination with measles vaccine among doctors and the general public is very important. Our results suggest the possibility of gaps in the protection against measles in adults born during the execution of one dose of measles vaccine and supplemental immunization activities to prioritize targeting adults in Vojvodina, Serbia.

Point-of-care (POC) hemoglobin testing has the potential to Porcine Clia Kits revolutionize the strategy of massive transfusion. No previous studies have compared the POC and central laboratory testing of hemoglobin in patients undergoing major transfusions.We retrospectively compared the results of hemoglobin test point-of-care we (EPOC®) core laboratory to our complete blood count (CBC) test hemoglobin (Sysmex XE -5000 ™) in patients undergoing massive transfusion protocol (MTP) for bleeding. One hundred seventy paired samples from 90 patients for whom the activated MTP collected at a single tertiary care hospital between 10/2011 and 10/2017. 
Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.

Patients have both a EPOC® and CBC hemoglobin done within 30 minutes of each other during the MTP. We assess the accuracy EPOC® hemoglobin testing using two variables: the exchange and clinically significant differences from the CBC. The criteria Clinical Laboratory Improvement Amendments (CLIA) proficiency test for measurement defined exchange. Clinically significant difference between the test is defined by an expert panel.

Comments

Popular posts from this blog

Incidence of the 22q11.2 deletion in a large cohort of miscarriage samples.

BACKGROUND The 22q11.2 deletion syndrome is the most common microdeletion syndrome in live births, but data on the incidence in other populations is limited and also includes ascertainment bias. This study was designed to determine the incidence of miscarriage deletion 22q11.2  Human Clia Kits in samples sent for testing clinical molecular cytogenetics. RESULTS 6101 Twenty fresh products of conception (POC) samples were sent to CLIA- certified, CAP-accredited laboratory of April 2010 - May 2016 for miscarriage molecular cytogenetic testing using single nucleotide polymorphism (SNP) based microarray platform. A retrospective review determined 22q11.2 deletion events in this sample set. The results obtained in 22,451 fetuses (86%) cases, which, 15 (0.07%) had a microdeletion at 22q11.2 region (incidence, 1/1497). Of those, 12 (80%) cases were found in a sample of normal at a resolution karyotyping traditional (ie, no chromosomal abnormalities in over 10 Mb in size) and three cases (2...

Advances in hemoglobin A1c point of care technology.

Measurement of hemoglobin A1c (A1C) has long been accepted as the best indicator of glucose control over time. A1C tests for the technology used by both differences in costs (high pressure liquid chromatography) or structure (boronate affinity or immunoassay combined with general chemistry). This technology is commonly used in expensive laboratory instruments. More recently, technology A1C has been put into place care (POC) devices, allowing for the availability  Simian Clia Kits of measurement of A1C, greatly facilitate diabetes care in both specialist and general practice.  A1C POC tests must have acceptable performance, standardization of national reference, the National Glycohemoglobin Standardization Program (NGSP) certification, simple operation without the need for expensive instrumentation, and the Clinical Laboratory Improvement Amendments (CLIA) waiver. CLIA-waived POC technologies including Bio-Rad MicroMat II (distributed by a Cholestech GDX) and Axis-Shield Afi...